PubRank

Stephen L George

Author PubWeight™ 48.49‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Processes to activate phase III clinical trials in a Cooperative Oncology Group: the Case of Cancer and Leukemia Group B. J Clin Oncol 2006 4.91
2 Dose escalation studies of cytarabine, daunorubicin, and etoposide with and without multidrug resistance modulation with PSC-833 in untreated adults with acute myeloid leukemia younger than 60 years: final induction results of Cancer and Leukemia Group B Study 9621. J Clin Oncol 2004 2.49
3 The Society for Clinical Trials supports United States legislation mandating trials registration. Position paper. Clin Trials 2004 2.21
4 Flaxseed supplementation (not dietary fat restriction) reduces prostate cancer proliferation rates in men presurgery. Cancer Epidemiol Biomarkers Prev 2008 1.99
5 Phase 3 study of the multidrug resistance modulator PSC-833 in previously untreated patients 60 years of age and older with acute myeloid leukemia: Cancer and Leukemia Group B Study 9720. Blood 2002 1.95
6 Admissible two-stage designs for phase II cancer clinical trials. Stat Med 2004 1.77
7 Recombinant interleukin-2 in patients aged younger than 60 years with acute myeloid leukemia in first complete remission: results from Cancer and Leukemia Group B 19808. Cancer 2013 1.48
8 Overcoming challenges in designing and implementing a phase II randomized controlled trial using a presurgical model to test a dietary intervention in prostate cancer. Clin Trials 2008 1.48
9 Low-dose interleukin-2 immunotherapy does not improve outcome of patients age 60 years and older with acute myeloid leukemia in first complete remission: Cancer and Leukemia Group B Study 9720. J Clin Oncol 2008 1.45
10 P-glycoprotein inhibition using valspodar (PSC-833) does not improve outcomes for patients younger than age 60 years with newly diagnosed acute myeloid leukemia: Cancer and Leukemia Group B study 19808. Blood 2010 1.41
11 Comparison of reduced-intensity hematopoietic cell transplantation with chemotherapy in patients age 60-70 years with acute myelogenous leukemia in first remission. Biol Blood Marrow Transplant 2011 1.29
12 A multiple testing procedure to associate gene expression levels with survival. Stat Med 2005 1.22
13 Statistical challenges in preprocessing in microarray experiments in cancer. Clin Cancer Res 2008 1.19
14 Sequential multiagent chemotherapy is not superior to high-dose cytarabine alone as postremission intensification therapy for acute myeloid leukemia in adults under 60 years of age: Cancer and Leukemia Group B Study 9222. Blood 2004 1.14
15 Selection bias, phase II trials, and the FDA accelerated approval process. J Natl Cancer Inst 2003 1.12
16 Randomized clinical trial design for assessing noninferiority when superiority is expected. J Clin Oncol 2007 1.04
17 P-value calculation for multistage phase II cancer clinical trials. J Biopharm Stat 2006 1.02
18 A permutation-based multiple testing method for time-course microarray experiments. BMC Bioinformatics 2009 1.00
19 Postremission therapy with low-dose interleukin 2 with or without intermediate pulse dose interleukin 2 therapy is well tolerated in elderly patients with acute myeloid leukemia: Cancer and Leukemia Group B study 9420. Clin Cancer Res 2002 1.00
20 Satisfaction of the uncertainty principle in cancer clinical trials: retrospective cohort analysis. BMJ 2004 0.98
21 permGPU: Using graphics processing units in RNA microarray association studies. BMC Bioinformatics 2010 0.96
22 Managing accrual in cooperative group clinical trials. J Clin Oncol 2004 0.95
23 The long-term clinical course of patients with cutaneous melanoma. Cancer 2002 0.90
24 Individual patient data meta-analysis of randomized trials evaluating IL-2 monotherapy as remission maintenance therapy in acute myeloid leukemia. Blood 2011 0.89
25 Between-arm comparisons in randomized Phase II trials. J Biopharm Stat 2009 0.87
26 Data monitoring and large apparent treatment effects. Control Clin Trials 2004 0.87
27 Clinical trials data collection: when less is more. J Clin Oncol 2010 0.85
28 Response rate as an endpoint in clinical trials. J Natl Cancer Inst 2007 0.84
29 Medulloblastoma and birth date: evaluation of 3 U.S. datasets. Arch Environ Health 2004 0.84
30 Flexible Phase I Clinical Trials: Allowing for Nonbinary Toxicity Response and Removal of Other Common Limitations. Stat Biopharm Res 2009 0.81
31 Impact of race on survival in men with metastatic hormone-refractory prostate cancer. Urology 2004 0.80
32 Should statisticians reporting to data monitoring committees be independent of the trial sponsor and leadership? Stat Med 2004 0.80
33 Gene selection using iterative feature elimination random forests for survival outcomes. IEEE/ACM Trans Comput Biol Bioinform 2012 0.80
34 Multiple testing for gene sets from microarray experiments. BMC Bioinformatics 2011 0.79
35 A general formulation for a one-sided group sequential design. Clin Trials 2005 0.78
36 Sample size calculation for simulation-based multiple-testing procedures. J Biopharm Stat 2005 0.78
37 ROC curve estimation under test-result-dependent sampling. Biostatistics 2012 0.77
38 Multiple testing of treatment-effect-modifying biomarkers in a randomized clinical trial with a survival endpoint. Stat Med 2011 0.77
39 Sample size calculation for microarray experiments with blocked one-way design. BMC Bioinformatics 2009 0.75
40 Robust test method for time-course microarray experiments. BMC Bioinformatics 2010 0.75
41 Tomorrow's cancer treatments today: the first 50 years of the Cancer and Leukemia Group B. Semin Oncol 2008 0.75